← Back to Search

Cystic fibrosis patients for Cystic Fibrosis

N/A
Waitlist Available
Led By Amanda Dye, MD
Research Sponsored by CAMC Health System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months
Awards & highlights

Summary

Cystic fibrosis is an inherited disorder that causes severe damage to the lungs, digestive system, and other organs in the body. Individuals with cystic fibrosis often have poor weight gain and growth that can negatively impact health further by worsening lung function. Additionally, persons with the disease typically need more than the usual calories on a daily basis. Most institutions estimate these patients' caloric needs using weight, age, and sex based mathematical formulae. However, numerous studies show that use of these formulae often yields inaccurate caloric values. Use of indirect calorimetry may give more accurate estimates of caloric needs in patients with cystic fibrosis. The aim of our study is to assess the accuracy of caloric estimates generated using one such widely used mathematical formula, the Harris-Benedict equation, and to compare this calorie value with that obtained from indirect calorimetry testing in pediatric and adult patients with cystic fibrosis. Study investigators will use the newly calculated caloric requirements in dietary counseling. Changes in weight and lung function after 3 months will be compared to participants' historical changes.

Eligible Conditions
  • Cystic Fibrosis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Changes in pulmonary function status
Morphological variable changes
Resting energy expenditure estimation

Trial Design

1Treatment groups
Experimental Treatment
Group I: Cystic fibrosis patientsExperimental Treatment1 Intervention
Patients with cystic fibrosis who are six year or older, who regularly receive care at the West Virginia University-Charleston Cystic Fibrosis Center, and agreed to participate in the study.

Find a Location

Who is running the clinical trial?

CAMC Health SystemLead Sponsor
45 Previous Clinical Trials
7,986 Total Patients Enrolled
Amanda Dye, MDPrincipal Investigator - CAMC and WVU-Charleston
Charleston Area Medical Center-Women's & Children's Hospital
West Virginia University School Of Medicine (Medical School)
~12 spots leftby Sep 2025